|Bid||2.5200 x 4000|
|Ask||2.5300 x 2900|
|Day's Range||2.2700 - 2.5650|
|52 Week Range||2.1400 - 18.5000|
|Beta (3Y Monthly)||2.09|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Endo (ENDP) beats on both sales and earnings in the second quarter of 2019. However, both metrics decline year over year due to weak generic business.
Endo (ENDP) delivered earnings and revenue surprises of 10.64% and 0.37%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Endo (ENDP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Three pharmaceutical companies collectively are agreeing to pay California nearly $70 million to settle allegations that they delayed drugs to keep prices high, California Attorney General Xavier Becerra said Monday.
If you're interested in Endo International plc (NASDAQ:ENDP), then you might want to consider its beta (a measure of...
Investors love a turnaround play, and Wall Street is littered with stories of fortunes made betting on troubled companies.In the 1960s, American Express (AXP) was rumored to be near bankruptcy when Warren Buffett famously entered what is now one of his favorite Berkshire Hathaway positions. Apple (AAPL), which became the first U.S. company to hit $1 trillion in market value, absorbed more than a decade of losses during the 1980s and '90s before Steve Jobs helped turn the company around - aided by a $150 million investment from Microsoft (MSFT).But while every beat-up stock is a potential turnaround play, not every company achieves that potential. And losses can mount quickly for a stock that's already up against the ropes. So while you might be tempted to dabble in a potential comeback story or two, beware of some of the most common traps that end in disaster.Sometimes the issue is too much debt; rising interest costs and balloon payments can turn minor business setbacks into major liquidity challenges. Other times, once-powerful consumer brands are brought to their knees by management that's too slow to adapt to evolving consumer tastes.Certain areas of the market can be particularly prone to disasters. Start-up biotech stocks are risky because they're racing against the clock to bring new drugs to market before their cash runs out. Disappointing clinical trial result, in these cases, can cut a stock's value in half (or worse) within days. Chinese stocks are problematic, too, because of sometimes poor visibility and weak corporate governance.Here are 13 stocks to sell if you own them, or avoid if you're on the hunt for the next turnaround story. The companies themselves aren't necessarily an extinction threat, but for varying reasons, they're all on the brink of delivering more disastrous returns. SEE ALSO: Beware the Risks in These 13 Blue-Chip Stocks
Endo (ENDP) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Shares of Teva (TEVA) are on a downtrend on the risk of high litigation costs related to opioid epidemic in the United States. Morgan Stanley downgrades its rating on Teva.
Teva Pharmaceuticals (NYSE:TEVA) is having a Monday of nightmares as some of the company's products have led to lawsuits, which brought about a major analyst downgrade, causing TEVA stock to plummet early in the week.Source: Shutterstock The Israel-based pharma business with a global reach suffered today as the company's opioid-linked litigation has only started to kick off, with thousands of new lawsuits on the horizon. The harmful painkillers recently led to a judge giving the green light for an $85 million settlement in the state of Oklahoma, ensuring that the company will not promote opioids in the state.This is only the tip of the iceberg for Teva, which had a Monday that saw Morgan Stanley lower the stock's rating from an Equal Weight to an Underweight. The firm added that its price target on TEVA stock has now decreased from $16 per share to $6 per share.InvestorPlace - Stock Market News, Stock Advice & Trading TipsMorgan Stanley analyst David Risinger noted that the pharmaceutical giant, as well as competitors such as Endo International PLC (NASDAQ:ENDP), are experiencing "underappreciated risks" coming from buying group pressure, which are now more negative than predicted.These include a rise in generic competition, as well as the aforementioned opioid-related suits. The note arrived soon after Argus Capital upped its rating on TEVA stock to a buy with a $12 price target on July 5, 2019.TEVA stock fell 7.5% by day's end, while ENDO stock slid 3.7%. More From InvestorPlace * 10 Best Dividend Stocks to Buy for the Rest of 2019 and Beyond * 7 Dependable Dividend Stocks to Buy * 7 Retail Stocks to Buy for the Second Half of 2019 * 10 Stocks to Sell for an Economic Slowdown The post Teva Pharmaceuticals News: Why TEVA Stock Is Sliding Today appeared first on InvestorPlace.
Pharmaceutical stocks have been under pressure for the past few trading days, but one Wall Street analyst said the worst is yet to come for a handful of specialty drugmakers. The Analyst Morgan Stanley ...
In a report midday Monday, RBC Capital Markets analyst Randall Stanicky wrote that he did not believe that the loan, which came from an existing revolving credit facility, was taken to pay a potential opioid settlement.
Moody's Investors Service ("Moody's") downgraded the ratings of Endo Luxembourg Finance I Company S.à.r.l., and other subsidiaries of Endo International plc (together, "Endo"). The Corporate Family Rating was downgraded to B3 from B2 and the Probability of Default Rating was downgraded to B3-PD from B2-PD.
Shares of drug makers were getting a nice boost in premarket trading Tuesday, after AbbVie Inc.'s deal to buy Allergan PLC for a 45% premium. The SPDR S&P Pharmaceuticals ETF rallied 2.2% ahead of the open. Besides the 31% jump in Allergan's stock, among other shares seeing nice gains in the premarket, Mylan N.V. rose 2.7%, Endo International PLC climbed 4.5%, Theravance Biopharma Inc. hiked up 4.2%, Mallinckrodt PLC tacked on 2.7% and Perrigo Co. PLC gained 2.2%. Meanwhile, Medicines Co.'s stock shed 4.6%, after the company announced late Monday the public offering of $150 million worth of common stock. The pharmaceuticals ETF has lost 7.7% over the past three months through Monday, while the S&P 500 has gained 5.3%.
In 2016 Paul Campanelli was appointed CEO of Endo International plc (NASDAQ:ENDP). This report will, first, examine...
It was a rough fourth quarter for many hedge funds, which were naturally unable to overcome the big dip in the broad market, as the S&P 500 fell by about 4.8% during 2018 and average hedge fund losing about 1%. The Russell 2000, composed of smaller companies, performed even worse, trailing the S&P by more […]